What is SynchroCare: Value Proposition
SynchroCare is a partnership program designed for clinicians to ensure the right patient receives the right treatment at the right time
Pump therapy
A care program for physicians offering pump treatment.
Optimise care
The objective is to optimise care for patients.
Quicker referrals
Our aim is to make the referral process quicker and simpler.
The right treatment
Offer the right treatment to the right patient at the right time.
Why SynchroCare?
Pump treatment is an effective therapy1-6,
when it's offered in the right way
Low doses
Expected to produce fewer side effects 1-6
Targeted
For effective spasticity or pain relief1-6
Objectives
Ensure
expertise
To optimize the level of expertise and education at every level in expert & referral centers
- Implanters
- Experts & team
- Referrers
- Patients
Patient pathway optimization
To offer the SynchroMed™ infusion pump at the right time to those patients lacking adequate treatment
Ensure quality &
long-term data
Ensure Intrathecal Drug Delivery gets embedded as a long-term treatment strategy and ensure reimbursement via correct use & long-term data
1
Smith T J, Staats P S, Deer T, Stearns L J, Rauck R L, Boortz-Marx R L, Buchser E, Català E, Bryce D A, Coyne P J and Pool G E 2002 Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drugrelated toxicity, and survival J. Clin. Oncol. 20 4040–9
2
Smith T J, Coyne P J, Staats P S, Deer T, Stearns L J, Rauck R L, Boortz-Marx R L, Buchser E, Català E, Bryce D A, Cousins M, Pool G E, Wallace M, Yaksh T, Magnuson S, Leung A, Ahadian F, Bullock S, McBeth M, Hoye A, Miguel R, Weitzner M A, Balducci L, Follett K, Hitchon P, Minore W S, Weiss H, Jaworowicz J, Croy S, Davis S, Grossman S, Grieb M, Carson L, Mitchell S, Stuckey M, Charapata S, McCracken M, Sorensen R, Calava J, Dunn J, Kosek P, Weinstein S, Banerjee T K, Caraway D, Kim C, Serafini M, McNeil K, Frame J, Orlandini G, Siragusa A, Aliaga F, Lopez-Pousa A, Pericay C, Perey L, Muriel C, Boyle F, Molloy A, Brooker C and Walker S E 2005 An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM) Ann. Oncol. 16 825–33
3
Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13(10):1304-1313. doi:10.1111/j.1526-4637.2012.01451.x
4
Grider JS, Etscheidt MA, Harned ME, et al. Trialing and Maintenance Dosing Using a Low-Dose Intrathecal Opioid Method for Chronic Nonmalignant Pain: A Prospective 36-Month Study. Neuromodulation. 2016;19(2):206-219. doi:10.1111/ner.12352
5
Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J Rehabil Med. 2017 Mar 6;49(3):193-203.
6
Meythaler JM, Guin-Renfroe S, Law C, et al. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents adults with cerebral palsy. Arch Phys Med Rehabil 2001;82(2):155-161.
Brief Statement
If you have any questions specific to the medicinal product that you are using this device to administer, please contact the Marketing Authorisation Holder.
When ITB is mentioned, we are considering Intrathecal baclofen (an anti-spastic) administered by an intrathecal drug delivery pump therapy. Medtronic provides only the intrathecal drug delivery pump and the catheter; the intrathecal baclofen, morphine or ziconotide is provided to the relevant healthcare professional by an external company.
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).
Please note that the intended use of a product may vary depending on geographical approvals.
See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.
If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com.
Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable).
For any further information, contact your local Medtronic representative.